Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

NCT06281886 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

170

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma
Efficacy
Toxicity

Interventions

DRUG: Induction Immunotherapy-Toripalimab
DRUG: Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin
RADIATION: Radiotherapy
DRUG: Apatinib
DRUG: Capecitabine

Sponsor

Sun Yat-sen University